Methods of using specific microRNA to identify subjects with non-small cell lung cancer likely or unlikely to respond to treatment with tyrosine kinase inhibitors such as erlotinib, sunitinib, or vandetanib methods of treating subjects based on identification of said subjects as likely to respond to treatment with tyrosine kinase inhibitors and kits that facilitate the performance of the methods are disclosed.
